Is Xtant Medical Holdings, Inc. overvalued or undervalued?

As of 15 May 2024, the valuation grade for Xtant Medical Holdings, Inc. has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued. Key financial ratios reveal a Price to Book Value of 2.21, an EV to EBIT of -16.64, and an EV to EBITDA of -38.64, all of which suggest underlying financial challenges.
In comparison to its peers, Xtant Medical's performance stands out negatively; for instance, Jin Medical International Ltd. has an EV to EBITDA of -14.2435, while Butterfly Network, Inc. shows a similar risky classification with an EV to EBITDA of -6.8977. Additionally, the company's recent stock performance has underperformed against the S&P 500, particularly over the past month, where it saw a decline of 19.92% compared to a 3.83% gain in the index. This combination of poor financial metrics and relative performance reinforces the conclusion that Xtant Medical Holdings, Inc. is overvalued at this time.